Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.

Gilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Gilead, a global biopharma co. pursuing innovation in virology, oncology and inflammation, offers a variety of career opportunities in an inclusive workplace where all can make an impact.

Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information.

At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in.

2 days ago · Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers.

Jan 20, 2025 · Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...

2 days ago · Gilead Sciences, Inc. announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes.

Jan 22, 2025 · Gilead had reached an inflection point with Galapagos. The original assets that had attracted the Big Pharma to sign a deal worth more than $5 billion in 2019 had failed. A new leadership team helmed by Johnson & Johnson alum Paul Stoffels was entrenching Galapagos into cell therapy, but Gilead already had this space covered with Kite Pharma, which it acquired in 2017 for nearly $12 billion.